SCHEMBL6099511

SCHEMBL6099511

CCCCCCCCn1cc(C2=CC(=O)NC2=O)c2cc(OCc3ccccc3)ccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.41
MAOA P21397 3/20 0.41
EGFR P00533 1/20 0.40
IGF1R P08069 1/20 0.40
FLT4 P35916 1/20 0.40
KDR P35968 1/20 0.40
CNR2 P34972 4/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
GSK3B P49841 1/20 0.40
QPCT Q16769 1/20 0.40
ICMT O60725 1/20 0.40
PDE2A O00408 2/20 0.39
PRKD1 Q15139 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
PPARA Q07869 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097466 0.87 MAOB (0.44) MAOBMAOAKDRCNR2MEN1
SCHEMBL6098592 0.86 PPARD (0.48) MAOBMAOAPPARGPPARDPPARA
SCHEMBL6799799 0.85 PPARG (0.41) MAOBMAOACNR2MEN1NPC1
SCHEMBL6099720 0.81 PPARD (0.50) MAOBMAOAPPARGPPARDPPARA
SCHEMBL6100791 0.80 PPARD (0.44) MAOBMAOAGSK3BTDP1PPARG
SCHEMBL6098735 0.79 BAZ2B (0.48) MAOBMAOACNR2MEN1NPC1
SCHEMBL7064807 0.78 MAPK1 (0.45) NPC1RAB9APPARGPPARDPPARA
SCHEMBL6100606 0.78 PPARD (0.46) MAOBMAOAEGFRIGF1RFLT4
SCHEMBL6100670 0.77 MAOB (0.43) MAOBMAOA
SCHEMBL6099154 0.76 HTR6 (0.52) MAOBMAOAMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US disclosed
US-20040220202-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-11-04 US disclosed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US disclosed
EP-1283836-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS Aegera Therapeutics Inc. (CA) 2003-02-19 EP disclosed
WO-2001087887-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220202-A1 Neuroprotective and anti-proliferative compounds NLN, MKI67, BDNF MAOB 859/4885MAOA 1148/4885EGFR 2719/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF MAOB 895/4885MAOA 1264/4885EGFR 2740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.